| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Martin Metz | Q37838546 |
| Marcus Maurer | Q50039778 | ||
| P2860 | cites work | Mouse and human eosinophils degranulate in response to platelet-activating factor (PAF) and lysoPAF via a PAF-receptor-independent mechanism: evidence for a novel receptor | Q24629279 |
| Rupatadine: pharmacological profile and its use in the treatment of allergic disorders | Q28266916 | ||
| Rupatadine in allergic rhinitis and chronic urticaria | Q28272573 | ||
| Rupatadine: a review of its use in the management of allergic disorders | Q28291250 | ||
| No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines. | Q33765011 | ||
| Allergic rhinitis and its impact on asthma | Q34438438 | ||
| Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis | Q34586645 | ||
| World Health Organization; GA(2)LEN; AllerGen. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) | Q34589248 | ||
| Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study. | Q34662960 | ||
| Allergic rhinitis management pocket reference 2008. | Q34806394 | ||
| EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria | Q35004490 | ||
| Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy | Q37348139 | ||
| Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper | Q37690393 | ||
| GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma 'epidemic'. | Q38437094 | ||
| Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers | Q39333625 | ||
| Rupatadine inhibits proinflammatory mediator secretion from human mast cells triggered by different stimuli | Q39813709 | ||
| In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. | Q40858913 | ||
| Pharmacokinetic and safety profile of rupatadine when coadministered with azithromycin at steady-state levels: a randomized, open-label, two-way, crossover, Phase I study. | Q42599570 | ||
| Safety of rupatadine administered over a period of 1 year in the treatment of persistent allergic rhinitis: a multicentre, open-label study in Spain | Q42608507 | ||
| Modern approaches to the diagnosis and treatment of cold contact urticaria | Q43072441 | ||
| Activation of human mast cells through the platelet-activating factor receptor | Q43099465 | ||
| Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. | Q43167471 | ||
| Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial | Q43268586 | ||
| Association of platelet-activating factor with primary acquired cold urticaria | Q44233417 | ||
| Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study | Q44924028 | ||
| Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers | Q45148117 | ||
| The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo- controlled treatment with rupatadine 10 and 20 mg. | Q45349463 | ||
| A 12-week placebo-controlled study of rupatadine 10 mg once daily compared with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis | Q46512096 | ||
| The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings | Q46835325 | ||
| Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber | Q46914336 | ||
| Epidemiology of urticaria: a representative cross-sectional population survey | Q48818614 | ||
| Do patients with skin allergies have higher levels of anxiety than patients with allergic respiratory diseases? Results of a large-scale cross-sectional study in a French population. | Q50937591 | ||
| Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. | Q50948117 | ||
| Rhinitis symptoms and comorbidities in the United States: burden of rhinitis in America survey. | Q52693172 | ||
| Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria | Q56984215 | ||
| P433 | issue | 1 | |
| P921 | main subject | urticaria | Q187440 |
| allergic rhinitis | Q272436 | ||
| P304 | page(s) | 15-20 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Expert Review of Clinical Immunology | Q15733763 |
| P1476 | title | Rupatadine for the treatment of allergic rhinitis and urticaria | |
| P478 | volume | 7 |
| Q51745540 | A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection. |
| Q91112869 | Angioedema and prescribing of omalizumab for chronic urticaria in countries with limited financial resources |
| Q48138298 | Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: a randomized, double-blind, 6-week trial |
| Q38062942 | Emerging drugs for perennial allergic rhinitis |
| Q36134701 | Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial. |
| Q36359983 | Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial |
| Q27311403 | Rupatadine protects against pulmonary fibrosis by attenuating PAF-mediated senescence in rodents |
| Q27022598 | Stress triggers coronary mast cells leading to cardiac events |
| Q38285821 | Update on rupatadine in the management of allergic disorders |
Search more.